Crohn's disease is extremely rare in infancy and can be present in severe forms. Infants with Crohn's disease might require intensive immunosuppressive therapy. Infliximab is a chimeric mouse/human monoclonal IgG1 antibody against tumor necrosis factor-α, and completely neutralizes its biologic activity. Though widely used in the treatment of pediatric Crohn's disease, there are few data regarding its applicability in infancy. We therefore report herein our experiences with infliximab therapy in two infantile patients with Crohn's disease who were resistant to conventional therapies; one patient showed a partial response while there was no response in the second. We were unable to achieve satisfactory results from infliximab therapy. It remains to be determined whether inflammatory bowel disease starting in infancy represents a separate pathogenetic subgroup and whether the inflammatory bowel disease diagnosis should follow the exclusion of an immunodeficiency state. Studies in larger series are needed to further clarify the efficacy, safety and timing of infliximab therapy for infantile Crohn's disease patients. © 2009 European Crohn's and Colitis Organisation.
Uslu, N., Usta, Y., Saltik-Temizel, I. N., Demir, H., Gürakan, F., Ozen, H., & Yüce, A. (2010). Ineffectiveness of infliximab therapy in severe infantile Crohn’s disease. Journal of Crohn’s and Colitis, 4(1), 106–109. https://doi.org/10.1016/j.crohns.2009.08.004